Agouron Acquires New Anti-HIV Drug from Shionogi [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

= 11111 I[JrIllIIIII I II l IlIl IlIII~lIIllIIII l IJJlJI iI
Ag ourcn. 5571095.0147010
Agouron o o 5~
PharmaceuUca, Inc. NEWS
Investor Contact: Media Contact:
Donna Nichols, Vice President Joy Schmitt, Manager
Head of Corporate Communications Product Public Relations
[phone] [phone]
For Release at 8:00 a.m. EDT on June 29, 1998
AGOURON ACQUIRES NEW ANTI-HIV DRUG FROM SHIONOGI
LA JOLLA, Calif., June 29, 1998 - Agouron Pharmaceuticals, Inc. (Nasdaq: AGPH)
today announced it will develop and commercialize S-1153, a second generation non-nucleoside
reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection. Discovered by
Shionogi & Co., Ltd., Osaka, Japan, S-1153 is currently the subject of several clinical trials
evaluating its dose and its concomitant use with other antiretroviral treatments. S-1153 is of high
clinical interest because it is more potent in vitro than other NNRTIs such as nevirapine
(Viramune~) and delavirdine (Rescriptor~) and because S-1153 is fully active in vitro against
HIV containing the most common genetic mutation associated with resistance to other NNRTIs
including efavirenz (SustivaTM).
Agouron will have exclusive rights to the development and commercialization of S-1153
in North America, Europe and many other countries, while Shionogi will maintain commercial
rights in Japan, Korea, and Taiwan. Under the agreement with Agouron, Shionogi will receive
license fees of up to $40 million, including an initial $10 million license fee. In addition,
Agouron will pay Shionogi royalties based on sales of S-1153.
Results from a phase I dose escalation pharmacokinetic and safety study of S-1153 will be
presented at the 12th World AIDS Conference this week by Bruce Dezube, M.D., principal
investigator, of the Beth Israel Deaconess Medical Center in Boston.
Developing compounds that work against antiretroviral-resistant strains of HIV is an
important goal in the treatment of HIV infection. Agouron will move swiftly to initiate additional
clinical trials of S-1153 to further evaluate its utility in patients with previous experience with
antiretroviral drugs.
Agouron Pharmaceuticals, Inc. is an integrated pharmaceutical company committed to the

discovery, development, manufacturing, and marketing of innovative therapeutic products
-more